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OBJECTIVE—Given the pleiotropic effect of eicosapentaenoic
acid (EPA), it is interesting to know whether EPA is capable of
improving obesity. Here we examined the anti-obesity effect of
EPA in mice with two distinct models of obesity.
RESEARCH DESIGN AND METHODS—Male C57BL/6J mice
were fed a high-fat/high-sucrose diet (25.0% [w/w] fat, 32.5%
[w/w] sucrose) (HF/HS group) or a high-fat diet (38.1% [w/w] fat,
8.5% [w/w] sucrose) (HF group) for 4–20 weeks. A total of 5%
EPA was administered by partially substituting EPA for fat in the
HF/HS  EPA and HF  EPA groups.
RESULTS—Both the HF/HS and HF groups similarly developed
obesity. EPA treatment strongly suppresses body weight gain
and obesity-related hyperglycemia and hyperinsulinemia in HF/
HS-fed mice (HF/HS  EPA group), where hepatic triglyceride
content and lipogenic enzymes are increased. There is no appre-
ciable effect of EPA on body weight in HF-fed mice (HF  EPA
group) without enhanced expression of hepatic lipogenic en-
zymes. Moreover, EPA is capable of reducing hepatic triglyceride
secretion and changing VLDL fatty acid composition in the
HF/HS group. By indirect calorimetry analysis, we also found
that EPA is capable of increasing energy consumption in the
HF/HS  EPA group.
CONCLUSIONS—This study is the ﬁrst demonstration that the
anti-obesity effect of EPA in HF/HS-induced obesity is associated
with the suppression of hepatic lipogenesis and steatosis. Be-
cause the metabolic syndrome is often associated with hepatic
lipogenesis and steatosis, the data suggest that EPA is suited for
treatment of the metabolic syndrome. Diabetes 59:2495–2504,
2010
T
he metabolic syndrome has been deﬁned as a
cluster of visceral fat obesity, impaired glucose
metabolism, atherogenic dyslipidemia (high
plasma triglyceride and low HDL cholesterol),
and hypertension (1). There is considerable evidence that
visceral fat obesity is a key etiological factor in the
metabolic syndrome (2). Enhanced hepatic lipogenesis
and hepatic steatosis also appear to play an important role
in the pathogenesis of the metabolic syndrome (3). Indeed,
nonalcoholic fatty liver disease may constitute the com-
mon features of the metabolic syndrome.
Numerous epidemiological studies and clinical trials
have revealed that ﬁsh oil and n-3 polyunsaturated fatty
acids (PUFAs) reduce the risk of coronary heart disease
(4). Eicosapentaenoic acid (EPA), one of the major n-3
PUFAs contained in ﬁsh oil, has a variety of pharmacolog-
ical effects such as lipid-lowering (5), anti-platelet (6),
anti-inﬂammatory (7), and anti-atherogenic effects (8,9).
Recently, the Japan EPA Lipid Intervention Study (JELIS),
a large-scale prospective randomized clinical trial, demon-
strated that EPA delays the onset of cardiovascular events
via cholesterol-independent mechanisms (10,11), but the
molecular mechanisms remain to be elucidated. In a
recent sub-analysis of the JELIS, EPA had a great risk
reduction of coronary artery events of 53% in patients with
high triglycerides and low HDL cholesterol (11), suggest-
ing that EPA may be effective to reduce the incidence of
atherosclerosis in the metabolic syndrome. These ﬁndings
are supported by our recent observations that EPA admin-
istration results in decreases in remnant-like particle-
triglyceride, small dense LDL, and C-reactive protein and
an increase in adiponectin in patients with the metabolic
syndrome (12,13).
Given the pleiotropic effect of EPA, it is interesting to
know whether highly puriﬁed EPA is capable of improving
obesity. There is currently a controversy as to the anti-
obesity effect of EPA; it has been effective (13,14), has
been ineffective (15), or has even increased visceral fat
accumulation (16). On the other hand, it is noteworthy that
EPA suppresses hepatic lipogenesis and steatosis by re-
ducing mRNA and active protein of sterol regulatory
element binding protein-1c (SREBP-1c) (17–19). We, there-
fore, examined the impact of hepatic lipogenesis on the
anti-obesity effect of highly puriﬁed EPA.
Here, we demonstrate that EPA strongly suppresses
body weight gain and obesity-related hyperglycemia and
hyperinsulinemia in high-fat (HF)/high-sucrose (HS)-in-
duced obese mice with enhanced hepatic lipogenesis but
not in HF-induced obese mice without enhanced hepatic
lipogenesis. This study is the ﬁrst demonstration that the
anti-obesity effect of EPA is related to the suppression of
hepatic lipogenesis. Given that the metabolic syndrome is
often associated with hepatic lipogenesis and steatosis,
the data of this study suggest that EPA is suited for the
treatment of the metabolic syndrome.
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Highly puriﬁed EPA ethyl ester (purity 98%) was obtained from Nippon
Suisan Kaisha (Tokyo, Japan). Ethyl palmitate (purity 95%) was purchased
from Wako (Tokyo). Nine-week-old male C57BL/6J mice were obtained from
CLEA Japan (Tokyo) and acclimated for 1 week before the experiment. Mice
were housed under controlled temperature and lighting (0730–1930 light,
1930–0730 dark cycle) with free access to water and a ﬁsh meal-free diet (ﬁsh
meal-free F1: 4.4% fat; Funabashi Farm, Funabashi, Japan). All experiments
were carried out in accordance with the guidelines for the use and care of
laboratory animals of Mochida Pharmaceutical (numbers 1523, 1524, 2354,
and 2389).
Diets. The outline of experiments and composition of diets are in supplemen-
tary Tables 1 and 2, respectively (available in an online appendix at
http://diabetes.diabetesjournals.org/cgi/content/full/db09-1554/DC1).
Plasma analysis. Blood samples were collected via the retro-orbital sinus of
nonfasted mice under light anesthesia every 2 weeks. Plasma glucose, total
cholesterol, triglycerides, free fatty acid, and insulin were determined by
commercially available kits. Plasma concentrations of leptin and adiponectin
were measured with the respective enzyme-linked immunosorbent assay kits
(leptin: Morinaga, Yokohama, Japan; adiponectin: R&D Systems, Minneapolis,
MN).
Hepatic triglyceride content. Liver lipids were extracted by the method of
Folch et al. (20). Hepatic triglyceride content was measured with a reagent
from Wako.
Gene expression analysis. Expression levels of some genes were deter-
mined by quantitative real-time PCR using primers and probes shown in
supplementary Table 3. Expression of other genes was determined using
TaqMan gene expression assays (Applied Biosystems, Foster City, CA). The
assay IDs of TaqMan (R) gene expression assays are shown in supplementary
Table 4. 18s rRNA was measured using TaqMan (R) rRNA control reagents
(Applied Biosystems) as a control.
Enzymatic activities. Acyl-CoA oxidase, fatty acid synthase (FAS), and
hydroxyacyl-CoA dehydrogenase activities were measured spectrophoto-
metrically (21–23).
Cytoplasmic and nuclear protein extracts and Western blot analysis.
Cytoplasmic and nuclear proteins were extracted as described (24,25) with
slight modiﬁcations. The samples were equally pooled from all the mice of
each group (n  7–10), and then 30 g protein per lane was separated by
SDS-PAGE. Western blot analysis was performed using anti–SREBP-1 anti-
body (H160; Santa Cruz Biotechnology, Santa Cruz, CA). We used anti–-actin
(Cell Signaling Technology, Beverly, MA) and anti-TATA binding protein
(TBP) (Abcam, Cambridge, U.K.) antibodies as cytoplasmic and nuclear
controls, respectively. The blots were visualized with the ECL Western
blotting analysis system (GE Healthcare, Buckinghamshire, U.K.).
Indirect calorimetry analysis. The volumes of consumed O2 (VO2) and
produced CO2 (VCO2) were measured by indirect calorimetry using an
Oxymax system (Columbus Instruments, Columbus, OH). The O2 and CO2
contents were recorded every 10 min from 1130 to 0900. Mice had unrestricted
access to food and water. The respiratory exchange ratio (RER) was calcu-
lated by VCO2/VO2.
Glycerol release from white adipose tissue. Glycerol release from the
epididymal fat ex vivo was measured according to the method of Schweiger et
al. (26) with slight modiﬁcations.
Hepatic triglyceride secretion rate. A dose of 500 mg/kg tyloxapol (also
known as Triton WR-1339; Sigma-Aldrich, St. Louis, MO) in saline was injected
intravenously. Mice were fasted overnight before the injection. Immediately
before and 1 h after the injection, blood samples were collected and plasma
triglyceride concentrations were determined as described above. The hepatic
triglyceride secretion rate was calculated as described by Steiner et al. (27).
Fatty acid composition of VLDL. Blood samples were collected via the
inferior vena cava of mice 4 h after the tyloxapol injection. Plasma was
isolated, and VLDL fraction was obtained by ultracentrifugation, according to
the method of Werner et al. (28). Fatty acid composition was analyzed by gas
chromatography.
Statistical analysis. Data are presented as means  SE. ANOVA using a
split-plot model was used for the line plots of indirect calorimetry analysis
(Fig. 6C and E). Other data were assessed by a t test. P  0.05 was considered
a signiﬁcant difference.
RESULTS
Effect of EPA on HF/HS- and HF-induced obesity.
Both HF/HS and HF groups gained weight with increases
in the mesenteric, epididymal, retroperitoneal, and subcu-
taneous white adipose tissue (WAT) weights relative to the
control group after a 20-week feeding (experiments 1 and
2) (Fig. 1A–D). There were no appreciable differences
between HF/HS and HF groups. The HF/HS-induced in-
creases in body weight and WAT weights were markedly
suppressed by treatment with EPA (HF/HS  EPA group).
By contrast, EPA treatment did not affect an HF-induced
increase in body weight and WAT weights (HF  EPA
group). In the HF/HS group, obesity-induced WAT inﬂam-
mation was evident, as revealed by elevated expression of
mRNAs for F4/80, monocyte chemoattractant protein-1
(MCP-1), and tumor necrosis factor-. EPA treatment
markedly reduced F4/80 and MCP-1 mRNA expression in
WAT (Fig. 1E). In WAT from the HF group, expression of
F4/80, MCP-1, and tumor necrosis factor- mRNAs was
elevated, which was not affected by EPA (Fig. 1F). In this
study, caloric intake in the HF/HS group was roughly
equivalent to that in the HF/HS  EPA group (Table 1).
Effect of EPA on HF/HS- and HF-induced metabolic
abnormalities. In experiment 1, the HF/HS group devel-
oped obvious hyperinsulinemia, hyperglycemia, and he-
patic steatosis, which were signiﬁcantly improved by EPA
(HF/HS  EPA group) (Fig. 2A, C, and E). The liver
weights after a 20-week feeding were 1.33  0.03, 3.10 
0.30, and 1.42  0.06 g in the control, HF/HS, and HF/HS 
EPA groups, respectively (n  10 for the control and
HF/HS groups, n  7 for the HF/HS  EPA group; P  0.01
for the control group versus HF/HS group and the HF/HS
group versus HF/HS  EPA group). Similarly, the HF
group developed hyperglycemia and hyperinsulinemia;
however, EPA had a marginal impact on HF-induced
hyperglycemia and hyperinsulinemia (Fig. 2B and D).
Although EPA treatment ameliorated hepatic steatosis in
the HF group (Fig. 2F), liver weight was not decreased by
EPA (data not shown). Plasma leptin concentrations were
markedly elevated in the HF/HS group relative to the
control group and were signiﬁcantly reduced by EPA (P 
0.01) (Table 1). Although HF/HS did not affect plasma
adiponectin concentration, EPA treatment resulted in an
	1.5-fold elevation of plasma adiponectin (Table 1), which
is consistent with our previous report (13).
Effect of EPA on gene expression in the HF/HS group.
Enhanced expression of genes related to -oxidation (29),
uncoupling proteins (UCPs) (30), and glucose oxidation
(31) are known to suppress obesity. However, they were
not reduced or rather elevated in the liver and WAT from
the HF/HS group relative to the control group (Fig. 3A and
E). Moreover, in the skeletal muscle, except UCP-3, gene
expression was not increased by EPA treatment (HF/HS 
EPA group) relative to the HF/HS group (Fig. 3C). These
observations suggest that enhancement of -oxidation,
UCPs, and glucose oxidation does not play a major role in
the anti-obesity effect of EPA.
Enhanced lipolysis may promote the degradation of
triglycerides accumulated in WAT, thereby leading to
the suppression of obesity. Expression of mRNAs for
hormone-sensitive lipase and adipose triglyceride lipase in
WAT from the HF/HS group did not differ signiﬁcantly
from that in the control group. On the other hand, expres-
sion of mRNAs for the 3-adrenergic receptor (3-AR),
triglyceride hydrolase (TGH)-1, and TGH-2 in the HF/HS
group was signiﬁcantly lower than in the control group
(P  0.01), which was reversed in the HF/HS  EPA group
(Fig. 3E).
It is also possible that enhanced lipogenesis promotes
energy accumulation through triglyceride synthesis from
diet-derived carbohydrates and fatty acids, thereby stimu-
lating obesity and WAT accumulation. In WAT, there was
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(ACC)-1 and FAS mRNA expression between the HF/HS
and control groups. Expression of ACC-1 and FAS mRNAs
was not increased in the HF/HS  EPA group relative to
the HF/HS group. Stearoyl-CoA desaturase (SCD)-1 mRNA
expression in the HF/HS group was elevated relative to the
control group, which was unaffected by EPA treatment
(Fig. 3E). In the liver, ACC-1, FAS, and SCD-1 mRNA
expression in the HF/HS group was elevated relative to the
control group, which was reduced by EPA treatment
(HF/HS  EPA group) (Fig. 3A). In this study, hepatic
SREBP-1 protein, a master regulator of lipogenic enzymes,
was also increased in the HF/HS group, which was re-
duced by EPA treatment (Fig. 3F).
Effect of EPA on enzymatic activity in the HF/HS
group. In this study, elevated enzymatic activities of
hepatic FAS and acyl-CoA oxidase in the HF/HS group
were reduced by EPA treatment (Fig. 3B). Elevated activ-
ities of hydroxyacyl-CoA dehydrogenase in the skeletal
muscle from the HF/HS group was also reduced by EPA
treatment (Fig. 3D).
Effect of EPA on gene expression and enzymatic
activity in the HF group. We next examined mRNA
levels and activities of lipogenic enzymes in the HF group,
where EPA did not improve obesity and WAT accumula-
tion (Fig. 1B and D). Notably, expression of mRNA for
lipogenic enzymes and FAS activity in the liver were not
elevated in the HF group relative to the control group (Fig.
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was reduced by a HF diet (Fig. 4E), suggesting that HF diet
induces obesity without enhancement of hepatic lipogen-
esis. Although EPA reduced FAS activity, mRNA of lipo-
genic enzymes was not affected by EPA (Fig. 4A and B).
Treatment with EPA did not affect the activities of -oxi-
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TABLE 1
Food intake and plasma parameters in experiment 1 and 2 at 18 weeks of feeding
Experiment 1 Experiment 2
Control HF/HS HF/HS  EPA Control HF HF  EPA
Food intake (kcal/day/mouse) 8.56 11.15 10.58 9.84 12.72 13.96
Leptin (ng/ml) 4.60  0.82 44.60  5.43†† 15.46  2.74** 6.46  0.67 47.02  5.39†† 36.24  5.55
Adiponectin (g/ml) 10.05  0.59 10.78  0.51 15.00  1.45* 10.85  0.92 14.51  0.76†† 15.33  1.03
Total cholesterol (mg/dl) 96.8  5.8 236.4  9.6†† 104.6  5.5** 101.6  3.7 193.6  7.3†† 109.2  7.2**
Triglyceride (mg/dl) 157.2  9.2 105.6  8.1†† 80.6  3.7* 143.6  11.6 113.2  12.4 88.0  4.6
Free fatty acid (mEq/l) 0.695  0.060 0.771  0.053 0.593  0.038* 0.670  0.022 0.681  0.059 0.663  0.025
Data are means  SE (n  7–10), except for food intake. The results of the food intake are presented as means of two cages. ††P  0.01
vs. the control group; *P  0.05; **P  0.01 vs. the HF (/HS) group.
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expression of lipogenesis or lipolysis-related proteins in
WAT from the HF group (Fig. 4B–D). Expression of
mRNAs for 3-AR and TGH-1 in WAT from the HF group
was lower than in the control group. TGH-2 mRNA expres-
sion tended to be low relative to the control group, but the
difference was not statistically signiﬁcant (Fig. 4D).
Effect of EPA on triglyceride secretion and VLDL
fatty acid composition in the HF/HS group. In the liver,
triglycerides are synthesized via lipogenesis and secreted
as VLDL, which in turn delivered to peripheral tissues such
as WAT. Evidence has suggested that some species of fatty
acids affect triglyceride accumulation in adipocytes (32).
We therefore examined hepatic triglyceride secretion and
VLDL fatty acid composition in the HF/HS group (experi-
ment 3). We found the enhanced secretion of triglycerides
in the HF/HS group relative to the control group (Fig. 5A).
Analysis of VLDL fatty acid composition revealed that
palmitic (C16:0), palmitoleic (C16:1 n-7), and oleic acids
(C18:1 n-9) are increased and stearic acid (C18:0) is
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(Fig. 5B). In this study, EPA (C20:5 n-3) was markedly
increased in VLDL obtained from the HF/HS  EPA group
relative to the HF/HS and control groups. Increased he-
patic triglyceride secretion and the aberrant VLDL fatty
acid composition in the HF/HS group were all reversed by
EPA treatment (Fig. 5A and B). Linoleic acid (C18:2 n-6)
was markedly decreased in both HF/HS and HF/HS  EPA
groups relative to the control group.
Effect of EPA on WAT lipolysis in the HF/HS group.
Because reduced expression of 3-AR, TGH-1, and TGH-2
mRNAs in WAT from the HF/HS group was restored by
EPA treatment (Fig. 3E), we examined the effect of EPA
on WAT lipolysis in the HF/HS group (experiment 4).
There was no signiﬁcant difference in glycerol release ex
vivo between HF/HS and control groups (Fig. 6A). Treat-
ment with isoproterenol, a -AR agonist, stimulated glyc-
erol release in the control group, which was markedly
reduced in the HF/HS group. Interestingly, glycerol release
with or without isoproterenol stimulation was higher in
the HF/HS  EPA group than in the HF/HS group (Fig. 6A).
Effect of EPA on energy consumption in the HF/HS
group. There was a marked difference in energy accumu-
lation between HF/HS and HF/HS  EPA groups, despite
similar caloric intake (Fig. 1 and Table 1). However,
except UCP-3 in the skeletal muscle, gene expression of
-oxidation enzymes and UCPs were unchanged by EPA
treatment (Fig. 3A, C, and E). Furthermore, the activities
of -oxidation–related enzymes were reduced by EPA
(Fig. 3B and D). We, therefore, examined the effect of EPA
on O2 consumption and RER using indirect calorimetry
(experiment 4). HF/HS feeding increased O2 consumption
and signiﬁcantly reduced RER 6 weeks after the experi-
ment (Fig. 6C–F). In this study, EPA treatment signiﬁ-
cantly increased the HF/HS-induced O2 consumption and
inhibited the HF/HS-induced decrease in RER throughout
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mouse) (Fig. 6C and E). The mean values of RER for the
light and dark cycles in the HF/HS  EPA group were
signiﬁcantly higher than those of the HF/HS group (P 
0.01) (Fig. 6F), whereas there was no signiﬁcant difference
in mean values of VO2 between HF/HS and HF/HS  EPA
groups (Fig. 6D). EPA also signiﬁcantly increased O2
consumption 2 weeks after the experiment (P  0.01)
(data not shown).
After 8 weeks of feeding, expression levels of mRNA of
UCP-1 in brown adipose tissue (BAT) were unchanged by
the HF/HS and HF/HS  EPA groups (Fig. 6B). There was
no signiﬁcant difference in UCP-3 mRNA expression in the
skeletal muscle among control, HF/HS, and HF/HS  EPA
groups (data not shown). EPA also suppressed body
weight gain (control group, 28.47  0.64 g; HF/HS group,
35.73  0.99 g; HF/HS  EPA group, 30.78  0.59 g) and
epididymal WAT accumulation (control group, 0.36 
0.04 g; HF/HS group, 1.51  0.14 g; HF/HS  EPA group,
0.80  0.07 g) (experiment 4). There was no appreciable
difference in caloric intake among control, HF/HS, and
HF/HS  EPA groups (control group, 14.48  2.03 kcal/
day/mouse; HF/HS group, 13.76  0.24 kcal/day/mouse;
HF/HS  EPA group, 12.36  0.67 kcal/day/mouse).
DISCUSSION
This study demonstrates that hepatic steatosis is more
severe in the HF/HS group than in the HF group. Hyper-
insulinemia also develops more rapidly in the HF/HS group
than in the HF group, although both HF/HS and HF groups
similarly develop obesity and WAT accumulation. In this
study, we found that EPA ameliorates HF/HS-induced
obesity, WAT inﬂammation, fatty liver, hyperinsulinemia,
and hyperglycemia. By contrast, there is no effect of EPA
on obesity in the HF group. These observations indicate
the differential effect of EPA on metabolic parameters
between HF/HS and HF groups. Expression and activities
of hepatic lipogenic enzymes are increased in the HF/HS
group, which are abolished by EPA treatment. By contrast,
expression of hepatic lipogenic enzymes is not increased
in the HF group, where EPA is ineffective against visceral
fat accumulation and obesity. It seems that the lower
expression of SREBP-1 in the HF/HS  EPA group results
in the reduction of hepatic lipogenic enzymes. These
observations, taken together, suggest that suppression of
enhanced hepatic lipogenesis contributes to the anti-
obesity effect of EPA. It is noteworthy that mice with
liver-speciﬁc disruption of SCD-1 are resistant to high-
carbohydrate diet–induced obesity but are sensitive to HF
diet–induced obesity (33). In this study, we conﬁrmed that
EPA markedly reduces hepatic lipogenic enzymes includ-
ing SCD-1. The phenotypic effect of liver-speciﬁc deﬁ-
ciency of SCD-1 is similar to that observed in this study,
thereby supporting the concept that EPA exerts the anti-
obesity effect at least in part through the suppression of
hepatic lipogenesis.
Deﬁcit of lipogenic enzymes or administration of lipo-
genic enzyme inhibitors has been reported to inhibit
obesity. For instance, administration of FAS inhibitors
lowers body weight by reducing food intake (34). Global
deﬁciency of ACC-2 (35) or SCD-1 (36) or administration
of antisense oligonucleotide against SCD-1 (37) also shows
resistance to obesity through enhanced expression of
-oxidation enzymes or UCPs. On the other hand, neither
anorectic effect nor upregulation of -oxidation enzymes
or UCPs has been reported with EPA. Then, how does
reduced hepatic lipogenesis inhibit obesity or triglyceride
accumulation in WAT? Here, we demonstrated that EPA
markedly suppresses the HF/HS-induced hepatic triglycer-
ide secretion and palmitic, palmitoleic, and oleic acids in
VLDL. In this study, despite the enhanced hepatic lipogen-
esis and triglyceride secretion, plasma triglyceride concen-
trations are reduced in the HF/HS group relative to the
control group. This may be because of HF/HS-induced
activation of lipoprotein lipase in WAT, as suggested
elsewhere (38). Previous studies with mice lacking VLDL
receptor or apolipoprotein E demonstrated that VLDL
metabolism is closely related to obesity (39,40). There are
also several previous reports showing the relationship
between triglycerides delivered from the liver and fat
accumulation in the adipose tissue. For instance, obese
subjects have exhibited enhanced VLDL-triglyceride secre-
tion from the liver (41). Moreover, adenoviral overexpres-
sion of diacylglycerol-acyl transferase-1, which catalyzes
the ﬁnal step of hepatic triglyceride synthesis, has resulted
in enhanced VLDL-triglyceride secretion and thus obesity
(42). On the other hand, there is a report that triglyceride
accumulation in WAT is enhanced by a certain species of
fatty acids such as oleic and palmitic acids, among which,
oleic acid tends to induce triglyceride accumulation in
3T3-L1 adipocytes (32). Moreover, plasma content of
palmitoleic acid is positively correlated with obesity in
humans (43,44). In this study, we showed that hepatic
expression of SCD-1 is enhanced in the HF/HS group and
is markedly suppressed by EPA. SCD-1 is known to
catalyze the conversion from stearic and palmitic acids to
oleic and palmitoleic acids, respectively. Increased oleic
and palmitoleic acids in VLDL and hepatic gene expression
of SCD-1 in the HF/HS group are both suppressed by EPA.
It is, therefore, conceivable that increases in the quantity
(i.e., secretion rate) and quality (i.e., fatty acid composi-
tion) of triglycerides delivered from the liver contribute to
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group. Collectively, we speculate that the anti-obesity
effect of EPA is due at least in part to its impact on the
quantity and quality of triglycerides through the suppres-
sion of hepatic lipogenesis.
Lipogenesis is an efﬁcient means to transform the energy
accumulated in the body but not to consume energy. Because
EPA results in marked reduction of body weight and fat
accumulation in the HF/HS group, it is obligatory that EPA
consumes energy. Here, we demonstrated that EPA en-
hances energy consumption and reverses the decreased RER
in the HF/HS group. In this regard, Rustan et al. (45) reported
that treatment with docosahexaenoic acid  EPA increases
RER, but they did not show increased energy consumption.
These observations suggest that energy accumulated not as
triglycerides is consumed inside and/or outside the liver.
Enhanced energy consumption accompanied by enhanced
expression of -oxidation enzymes and UCPs was reported
in SCD-1 knockout mice (36) and mice treated with antisense
oligonucleotides of SCD-1 (37). In this study, although EPA
strongly suppresses hepatic SCD-1 mRNA expression, it does
not enhance -oxidation enzymes and UCPs. There are
appreciable changes in gene expression, which suggests the
EPA-induced increase in energy consumption. Expression of
-oxidation and glucose oxidation genes in the liver, skeletal
muscle, and WAT is not increased by EPA treatment. More-
over, activities of acyl-CoA oxidase and hydroxyacyl-CoA
dehydrogenase in the liver and skeletal muscle, respectively,
were reduced by EPA, suggesting a minor contribution of
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sion is also supported by increased RER by EPA.
Expression of mRNAs for UCPs except UCP-3 in the
skeletal muscle is not also increased when treated with
EPA. Although UCP-3 mRNA expression in the skeletal
muscle is only slightly increased by EPA (experiment 1),
EPA fails to enhance expression of UCP-3 mRNA in the
skeletal muscle as well as UCP-1 mRNA in BAT in exper-
iment 4, suggesting a minor contribution of UCPs to
EPA-induced energy consumption. In this regard, our
preliminary data show no signiﬁcant increase in O2 con-
sumption in the HF  EPA group relative to the HF group
(data not shown). These observations, taken together,
suggest that the suppressed hepatic lipogenesis is related
to enhanced energy consumption in the HF/HS  EPA
group. The molecular mechanisms by which EPA en-
hances energy consumption remain to be elucidated. We
also found that EPA only partly restores the otherwise
reduced WAT lipolysis in the HF/HS group. Similar to the
HF/HS group, 3-AR, TGH-1, and TGH-2 mRNA expression
is reduced in the HF group, but EPA fails in the restoration
of the reduced gene expression. These observations sug-
gest that EPA restoration of lipolysis is the consequence of
the anti-obesity effect of EPA.
The mechanism underlying the anti-obesity effect of
EPA has not been extensively studied, and the anti-obesity
effect of EPA reported so far is somewhat controversial.
Indeed, there is a report showing that EPA does not
prevent visceral fat accumulation in rats with HF/HS-
induced obesity, where EPA was administered for a much
shorter period of time (15). On the other hand, Oh-i et al.
(16) reported that EPA promotes body weight gain in rats
fed an HF diet through the reduction of brain leptin
transport or leptin resistance. The authors used diet
without carbohydrate such as sucrose and fructose, when
EPA may not exert the anti-obesity effect. In this study, the
fatty acid composition was different between the HF/HS
and HF diets used. Although the difference might modify
the phenotype of our models, this would not invalidate our
conclusion on the association between the anti-obesity
effect of EPA and suppression of hepatic lipogenesis. In
analyzing the anti-obesity effect of EPA, we should be
careful of the doses of EPA administered, period of
administration, species of animals used, etc., in addition to
the proportion of sucrose versus fat in the diet.
Given that hepatic lipogenesis in the HF group was
roughly comparable to that in control group, it is likely
that hepatic lipogenesis is less associated with HF-induced
obesity. This may be related to no appreciable anti-obesity
effect of EPA in the HF group, even with a downregulation
of hepatic lipogenic genes. In this regard, Kuda et al. (46)
reported that treatment with ﬁsh oil tends to prevent
HF-induced body weight gain, although not with statistical
signiﬁcance. This may be because of the potential differ-
ence in the anti-obesity effect between EPA used in this
study and ﬁsh oil or the doses of administration. On the
other hand, EPA reduced hepatic triglyceride in both the
HF/HS and HF groups. Rustan et al. (47) reported that EPA
inhibits incorporation of other fatty acids into triglyceride,
which may explain the EPA-induced reduction of hepatic
triglyceride accumulation in the HF group.
In conclusion, this study is the ﬁrst demonstration that
EPA prevents visceral fat accumulation and obesity, possibly
through the suppression of hepatic lipogenesis and enhance-
ment of energy consumption (Fig. 7). Because the metabolic
syndrome is often associated with enhanced lipogenesis and
steatosis or nonalcoholic fatty liver disease, this study sug-
gests that EPA may be effective to improve visceral fat
accumulation and hepatic steatosis in patients with the
metabolic syndrome. Our data also suggest that EPA is suited
for the treatment of the metabolic syndrome.
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